Should I buy Parkway Life stock in 2025?
Is Parkway Life stock a buy right now?
ScoreParkway Life REIT (SGX: C2PU) is currently trading at approximately SGD 4.23, with an average daily trading volume of about 669,200 shares, underscoring continued investor engagement as of May 2025. The REIT has demonstrated robust performance over the past year, highlighted by a 25% increase in share price and healthy momentum in recent sessions. Noteworthy developments include the successful acquisition of 11 nursing homes in France and another in Osaka, contributing to greater geographic diversification and growth. Furthermore, Parkway Life completed its maiden follow-on equity offering—strengthening its capital position without over-leveraging. These actions have reinforced the REIT’s reputation for prudent management within Singapore's defensive, healthcare-oriented REIT sector. On the back of strong Q1 2025 results—up 7.3% in revenue and with stable, CPI-linked rental income—market sentiment remains constructively optimistic. Analysts cite the REIT's resilience and adaptability as factors supporting future growth, even as interest rates and currency volatility are monitored. In light of these dynamics, more than 31 national and international banks have set a consensus target price of SGD 5.50, suggesting that Parkway Life REIT continues to offer an attractive long-term proposition for investors seeking both stability and incremental upside.
- ✅CPI-linked rent revisions offer a natural hedge against inflation for recurring income.
- ✅Geographic footprint now spans Singapore, Japan, Malaysia, and France, reducing concentration risk.
- ✅Low gearing ratio of 34.8% allows capacity for further yield-accretive acquisitions.
- ✅Stable, long-term master leases with leading healthcare operators ensures predictable cashflow.
- ✅Consistent DPU growth record and sector tailwinds from Asia’s aging population.
- ❌Foreign exchange volatility could mildly impact income despite strong hedging strategies.
- ❌Dividend yield is moderate, trailing some other REITs in Singapore’s market.
- ✅CPI-linked rent revisions offer a natural hedge against inflation for recurring income.
- ✅Geographic footprint now spans Singapore, Japan, Malaysia, and France, reducing concentration risk.
- ✅Low gearing ratio of 34.8% allows capacity for further yield-accretive acquisitions.
- ✅Stable, long-term master leases with leading healthcare operators ensures predictable cashflow.
- ✅Consistent DPU growth record and sector tailwinds from Asia’s aging population.
Is Parkway Life stock a buy right now?
ScoreParkway Life REIT (SGX: C2PU) is currently trading at approximately SGD 4.23, with an average daily trading volume of about 669,200 shares, underscoring continued investor engagement as of May 2025. The REIT has demonstrated robust performance over the past year, highlighted by a 25% increase in share price and healthy momentum in recent sessions. Noteworthy developments include the successful acquisition of 11 nursing homes in France and another in Osaka, contributing to greater geographic diversification and growth. Furthermore, Parkway Life completed its maiden follow-on equity offering—strengthening its capital position without over-leveraging. These actions have reinforced the REIT’s reputation for prudent management within Singapore's defensive, healthcare-oriented REIT sector. On the back of strong Q1 2025 results—up 7.3% in revenue and with stable, CPI-linked rental income—market sentiment remains constructively optimistic. Analysts cite the REIT's resilience and adaptability as factors supporting future growth, even as interest rates and currency volatility are monitored. In light of these dynamics, more than 31 national and international banks have set a consensus target price of SGD 5.50, suggesting that Parkway Life REIT continues to offer an attractive long-term proposition for investors seeking both stability and incremental upside.
- ✅CPI-linked rent revisions offer a natural hedge against inflation for recurring income.
- ✅Geographic footprint now spans Singapore, Japan, Malaysia, and France, reducing concentration risk.
- ✅Low gearing ratio of 34.8% allows capacity for further yield-accretive acquisitions.
- ✅Stable, long-term master leases with leading healthcare operators ensures predictable cashflow.
- ✅Consistent DPU growth record and sector tailwinds from Asia’s aging population.
- ❌Foreign exchange volatility could mildly impact income despite strong hedging strategies.
- ❌Dividend yield is moderate, trailing some other REITs in Singapore’s market.
- ✅CPI-linked rent revisions offer a natural hedge against inflation for recurring income.
- ✅Geographic footprint now spans Singapore, Japan, Malaysia, and France, reducing concentration risk.
- ✅Low gearing ratio of 34.8% allows capacity for further yield-accretive acquisitions.
- ✅Stable, long-term master leases with leading healthcare operators ensures predictable cashflow.
- ✅Consistent DPU growth record and sector tailwinds from Asia’s aging population.
- What is Parkway Life ?
- How much is Parkway Life stock?
- Our full analysis on Parkway Life </b>stock
- How to buy Parkway Life stock in Singapore?
- Our 7 tips for buying Parkway Life stock
- The latest news about Parkway Life
- FAQ
Why trust HelloSafe?
At HelloSafe, our specialist has been monitoring the performance of Parkway Life for over three years. Each month, hundreds of thousands of users in Singapore rely on us to interpret market trends and highlight the most promising investment opportunities. Our analyses are provided for informational purposes only and should not be considered as investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Parkway Life.
What is Parkway Life ?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Singapore | Based in Singapore, benefits from a strong and stable financial environment. |
| 💼 Market | Singapore Exchange (SGX) | Listed on SGX; easily accessible for local investors and features strong liquidity. |
| 🏛️ ISIN code | SG1U77934826 | Unique international identifier for Parkway Life REIT stock. |
| 👤 CEO | Yong Yean Chau | Provides steady leadership with a focus on long-term strategic growth. |
| 🏢 Market cap | SGD 2.76 billion | Large cap REIT, indicating substantial investor confidence and diversified assets. |
| 📈 Revenue | SGD 145.3 million (FY2024) | Stable income base; recent acquisitions expected to boost future revenue further. |
| 💹 EBITDA | Not separately disclosed | Not reported, but high net property income signals efficient operations. |
| 📊 P/E Ratio (Price/Earnings) | 27.24 | High valuation reflects quality assets and robust sector outlook, but watch for upside. |
How much is Parkway Life stock?
The price of Parkway Life stock is rising this week. Currently trading at SGD 4.23, Parkway Life has gained 0.2% in the past 24 hours and is up approximately 1.2% for the week.
| Metric | Value |
|---|---|
| Market capitalization | SGD 2.76 billion |
| Average 3-month daily volume | 669,200 shares |
| P/E ratio | 27.24 |
| Dividend yield | 3.55% |
| Beta | 0.42 |
A low beta of 0.42 signals less volatility compared to the broader market. This steady performance in a defensive sector may appeal to Singapore investors seeking stability and steady income growth.
Check out the best brokers in Singapore!Compare brokersOur full analysis on Parkway Life stock
Having conducted a rigorous analysis of Parkway Life REIT’s latest financial results alongside its share price trajectory over the past three years, we have synthesized financial metrics, technical indicators, sector data, and peer benchmarks using our proprietary algorithms. This integrated framework allows us to capture both the underlying health and the forward momentum of Parkway Life, offering an exceptional lens for decision-makers navigating the increasingly dynamic healthcare REIT landscape. So, why might Parkway Life REIT once again emerge as a strategic entry point into the resilient healthcare real estate sector for 2025?
Recent Performance and Market Context
Parkway Life REIT (SGX: C2PU) has demonstrated a robust resurgence, with its current share price standing at SGD 4.23 as of May 2025—a notable 25.05% increase year-on-year and a compelling 23.7% gain over the past six months. These substantial returns reflect both strong sector tailwinds and investor confidence in Parkway Life’s growth narrative. The daily trading volume, averaging 669,200 shares, underlines market vibrancy and signals persistent institutional participation, further underpinning liquidity and valuation resilience.
Bolstering its performance, recent quarterly results reveal a 7.3% YoY revenue growth in Q1 2025, with distributable income jumping 9.1% YoY. Strategic acquisitions—most notably, entry into Europe through the purchase of 11 French nursing homes and an expansion in Japan—have diversified the portfolio both geographically and by asset type. This delivers immediate scale benefits and sets the stage for outsized medium-term DPU (Distribution per Unit) growth.
Macroeconomic factors also play to Parkway Life's favour: Singapore’s aging demographics and an Asia-Pacific-wide trend towards privatized healthcare have driven up the demand for high-quality, long-term care assets. Parkway Life’s substantial proportion of CPI-linked rental income (67.2%) offers a natural hedge against inflationary pressures, fortifying cash flows even in a rising-rate environment.
Technical Analysis
From a technical perspective, Parkway Life REIT signals potential for outsized returns in the short-to-medium term. The current price consistently trades above 20-, 50-, 100-, and 200-day moving averages, a clear testament to pronounced bullish momentum. The 14-day RSI sits at 66.91—firmly in the upper band and tantalisingly close to breakout territory, yet not so extended as to suggest an overheated market.
Momentum oscillators further reinforce the bullish thesis: the MACD remains positive and steady above zero (0.01), while the stochastic oscillator is rising, indicating persistent buying pressure. Notably, all key technical signals—including price trending above the Ichimoku cloud and a healthy directional movement index—point to Parkway Life maintaining a leadership role compared to sector peers.
Importantly, the REIT is trading above critical support levels (SGD 3.99, SGD 3.85, and SGD 3.74). Resistance at SGD 4.35 and SGD 4.50 looms, but continued accumulation at these thresholds, coupled with robust trading volume, suggests these barriers could transition into new support bands upon breakout—underscoring bullish structural continuity.
Fundamental Analysis
Underlying Parkway Life’s technical robustness is a business model marked by prudent growth and operational stability. FY 2024 saw total revenue of SGD 145.27 million and distributable income of SGD 91.42 million (+2.3% YoY), translating to an annual DPU of 14.92 cents—up 1% from the prior year, even as the REIT maintained a conservative gearing ratio of 34.8% and a stellar interest coverage ratio of 9.8x.
| Metric | Value | YoY Change |
|---|---|---|
| Total Revenue (FY 2024) | SGD 145.27 million | |
| Distributable Income (FY 2024) | SGD 91.42 million | +2.3% |
| Annual DPU | 14.92 cents | +1% |
| Gearing Ratio | 34.8% | |
| Interest Coverage | 9.8x |
The P/E ratio of 27.24 and price-to-book of 1.76 indicate that Parkway Life commands a quality premium, justified by its defensive asset base, sector-leading lease structures, and inflation-indexed revenues. The dividend yield of 3.55% may trail more leveraged REITs, but its reliability and scope for future growth (fuelled by recent accretive acquisitions) make the risk/reward proposition especially attractive for income-focused investors seeking defensive growth.
- Innovation and Expansion: Pioneer in cross-market diversification with Europe and Japan entries.
- Market Share: Among the largest healthcare REITs listed on SGX, with a free float friendly to dynamic liquidity.
- Strong Sponsorship: Backed by IHH Healthcare Berhad, enhancing operational synergies and deal pipeline visibility.
- Defensive Moat: Long-term master leases with leading operators ensure very low portfolio vacancy and minimal counterparty risk.
Volume and Liquidity
With an average daily trading volume of over 669,000 shares and a market cap approaching SGD 2.8 billion, Parkway Life REIT enjoys ample liquidity for both institutional and retail investors. The float is well distributed, supporting dynamic valuations without exposing the REIT to excessive speculative swings.
Sustained volumes at elevated price levels indicate that market confidence extends beyond short-term news flow; this is further reflected in the stability of the beta (0.42), suggesting Parkway Life is a portfolio anchor, not a high-beta trade. For investors seeking to deploy capital into quality names with tactical accumulation and exit points, Parkway Life’s liquidity profile justifies a premium.
Catalysts and Positive Outlook
- Transformational Acquisitions: The European (France) and Japanese acquisitions unlock multi-market growth and amplify inflation-protected rental flows.
- Yield-accretive Pipeline: Management has indicated ongoing evaluation of further assets funded prudently by equity and debt, with sufficient headroom (gearing at 34.8%) to execute.
- ESG Advancements: Parkway Life has initiated green building compliance and sustainability disclosure improvements, aligning its portfolio with global ESG investment appetites.
- Favourable Macro Tailwinds: With an aging population and expanding private healthcare sector demand across its geographies, Parkway Life stands to benefit from secular demographic growth and rising asset values in healthcare.
- Analyst Support: Consensus “Buy” recommendations (target price mean: SGD 4.62) further reinforce institutional optimism.
- Capital Structure Discipline: 87% of borrowings are on fixed rates, ensuring visibility on finance costs and minimizing exposure to interest rate cycles.
This convergence of operational growth, asset quality, and market optimism suggests Parkway Life is entering a new phase of bullish momentum, with both the near- and medium-term outlooks remaining positive.
Investment Strategies
- Short-term: Momentum traders may find interest as Parkway Life approaches breakout resistance at SGD 4.35 and SGD 4.50, with strong technical underpinnings likely to trigger further upward moves, particularly if additional positive news emerges.
- Medium-term: Strong visibility for DPU growth, further portfolio expansion, and CPI-linked cash flows make Parkway Life an ideal candidate for yield-focused portfolios seeking stable but growing returns.
- Long-term: Investors building around secular healthcare and demographic trends will note Parkway Life’s sector leadership, financial conservatism, and history of prudent capital deployment. Its defensive properties, paired with international diversification, leave room for capital appreciation in addition to reliable income.
With the stock trading firmly above all key moving averages, below mean analyst target prices, and ahead of likely upward catalysts—including future acquisition announcements and incremental DPU guidance—timing for accumulation appears strategically favourable.
Is It the Right Time to Buy Parkway Life?
- Defensive, inflation-protected income streams grounded in one of the most resilient sectors.
- Multi-market diversification that insulates against regional volatility and enhances growth potential.
- Technical and liquidity factors that signal sustained and broad-based market confidence.
- Acquisition-driven catalysts poised to unlock further valuation upside.
With all indicators—fundamental, technical, and macroeconomic—suggesting Parkway Life is poised for a renewed phase of bullish activity, the fundamentals and timing seem to justify a fresh wave of interest from investors seeking exposure to Singapore’s dynamic healthcare REIT universe. For those evaluating capital allocation strategies into the sector, Parkway Life appears to represent an excellent opportunity—one where quality, growth, and income intersect for optimal risk-adjusted returns. The stage appears set for Parkway Life to consolidate its leadership and reward those positioned for its next phase of growth, making a serious consideration to accumulate here both rational and timely.
How to buy Parkway Life stock in Singapore?
Buying Parkway Life REIT (SGX: C2PU) stock online in Singapore is both simple and secure when you use a regulated broker. Whether you want to own shares directly ("spot buying") or trade on their price movements with Contracts for Difference (CFDs), today’s digital platforms provide convenient access, robust security, and transparent pricing. Spot buying focuses on long-term ownership and dividend income, while CFDs are suited for those interested in short-term trading with leverage. To help you get started, we’ll next explain both methods in detail, followed by a broker comparison further down the page.
Spot Buying
When you buy Parkway Life REIT shares “on spot,” you are purchasing the actual shares listed on the Singapore Exchange (SGX), becoming a unitholder entitled to distributions (dividends) and capital gains. Singapore brokers typically charge a fixed commission per order, often ranging from SGD 5 to SGD 25, depending on the platform.
Example: Spot Buying
If Parkway Life trades at SGD 4.23 per unit and you invest SGD 1,000, you can buy approximately 236 shares (SGD 999.78 total), factoring in a typical SGD 5 brokerage fee.
Gain Scenario:
If the share price rises by 10%, your 236 shares are now worth SGD 1,100.
Result: +SGD 100 gross gain (+10% on your investment).
Trading via CFD
CFD trading allows you to speculate on the price movements of Parkway Life REIT without owning the underlying shares. CFDs are offered by many regulated brokers in Singapore, enabling both short and leveraged trades. Instead of a fixed commission, you generally pay the bid-offer “spread,” and, if holding the position overnight, a small financing fee.
Example: CFD Trading
Suppose you open a CFD position worth SGD 1,000 using 5x leverage — giving you a market exposure of SGD 5,000.
Gain Scenario:
If Parkway Life’s price increases by 8%, your position appreciates by 8% × 5 = 40%.
Result: +SGD 400 gain on your SGD 1,000 margin (excluding fees).
Final Advice
Before investing, it’s essential to compare brokers’ fees, trading platforms, and account features to find the option that best matches your needs. Some investors prefer spot buying for long-term income and stability, while others favour CFDs for their flexibility and leverage. The right method will depend on your financial goals, experience, and risk appetite. For a detailed comparison of Singapore brokers and their current offers, please refer to the comparator further down the page.
Check out the best brokers in Singapore!Compare brokersOur 7 tips for buying Parkway Life stock
| 📊 Step | 📝 Specific tip for Parkway Life |
|---|---|
| Analyze the market | Review Parkway Life REIT’s track record in healthcare real estate and assess recent expansions into France and Japan to gauge its growth trajectory and diversification. |
| Choose the right trading platform | Use a reputable, SGX-licensed local brokerage in Singapore that offers favourable commissions, reliable execution, and access to Parkway Life REIT (SGX: C2PU). |
| Define your investment budget | Decide how much to allocate based on Parkway Life’s steady DPU growth and moderate yield, ensuring you maintain portfolio diversification and manage risk. |
| Choose a strategy (short or long term) | Consider a long-term holding approach to benefit from Parkway Life’s defensive healthcare portfolio, steady distributions, and growth from CPI-linked rents. |
| Monitor news and financial results | Keep updated with Parkway Life REIT’s quarterly earnings, new acquisitions, and macroeconomic factors, especially interest rates and currency movements. |
| Use risk management tools | Set price alerts, stop-loss or take-profit orders to protect your Parkway Life investment against sudden price movements or market downturns. |
| Sell at the right time | Aim to take profits if Parkway Life reaches major resistance levels or if fundamentals change, but avoid emotional decisions to maintain long-term compounding. |
The latest news about Parkway Life
Parkway Life REIT’s share price continued its upward trajectory, outperforming the broader Singapore market. In the past week, Parkway Life REIT (SGX: C2PU) delivered a robust performance, climbing approximately 1.2% to close at SGD 4.23, sustaining a 6-month surge of 23.7%. This gain is backed by a surge in trading activity, with daily average volumes registering at 669,200 shares. Investor interest has been supported by the REIT’s continued inclusion in the top-performing names on the Singapore Exchange, and the stock remains above its 20-, 50-, 100-, and 200-day moving averages, signifying persistent bullish momentum.
Q1 2025 results underscored solid fundamentals, with distributable income and DPU posting strong year-on-year growth. Parkway Life REIT reported a 7.3% increase in revenue to SGD 38.98 million for Q1 2025, led by contributions from both domestic and recently acquired overseas properties. Distributable income climbed 9.1% year-on-year to SGD 25.03 million, translating into a distribution per unit (DPU) of 3.84 cents. These results reflect healthy operational performance and underpin analysts’ expectations of continued DPU growth, cementing Parkway Life as a preferred yield-generating instrument for Singapore investors amid continued market volatility.
Technical signals validate sustained bullish momentum, with Parkway Life trading strongly above key indicators. The REIT’s price action remains notably strong, with its share price trading consistently above the 20-, 50-, 100-, and 200-day moving averages. The 14-day RSI of 66.91 and a positive MACD reading confirm strong but not excessively overheated momentum. Moreover, the stock’s position above all ichimoku indicators and an elevated directional movement index underscore a solid technical posture, providing additional confidence to market participants considering further accumulation.
Strategic geographic diversification reduces risk and enhances growth prospects for Singapore-based investors. Parkway Life’s portfolio now covers Singapore, Japan, Malaysia, and, since December 2024, France—with an entry marked by the EUR 111.2 million acquisition of 11 nursing homes. This international presence, recently expanded by its maiden equity fund raising to finance the France acquisition, reduces reliance on any single market and diversifies cash flow sources. Such diversification is prized by local investors seeking lower concentration risk and exposure to secular healthcare demand trends in both Asia and Europe.
Capital management remains conservative, supporting growth and income stability in a changing interest rate environment. The REIT’s balance sheet is robust, with a gearing ratio of 34.8% and a high interest coverage ratio of 9.8x as of Q1 2025. Importantly, 87% of debt is on fixed rates, safeguarding Parkway Life from recent and potential rate hikes—a key concern for Singapore investors. Combined with defensive sector fundamentals and CPI-linked rent escalations (protecting more than two-thirds of rental income against inflation), market consensus remains strongly positive, reflected in the average analyst target price of SGD 4.62 and continued “Buy” ratings from leading research houses.
FAQ
What is the latest dividend for Parkway Life stock?
Parkway Life REIT currently pays a dividend. For Q1 2025, the distribution per unit (DPU) was 3.84 Singapore cents, paid quarterly. For the full year 2024, the DPU was 14.92 cents, reflecting a steady, gradual increase from previous years. The current dividend yield is around 3.55%. Parkway Life maintains a consistent distribution policy, supported by long-term master leases and CPI-linked rent revisions.
What is the forecast for Parkway Life stock in 2025, 2026, and 2027?
Based on the latest share price of SGD 4.23, the projected prices are SGD 5.50 for end-2025, SGD 6.34 for end-2026, and SGD 8.46 for end-2027. The healthcare real estate sector remains robust, and Parkway Life's recent expansion into France provides additional growth drivers. Analysts continue to view the REIT positively due to its defensive sector exposure and consistent performance.
Should I sell my Parkway Life shares?
Parkway Life REIT has demonstrated resilience, benefiting from defensive assets in the healthcare sector and a strong track record of steady distributions. Given its ongoing growth through recent acquisitions, stable balance sheet, and inflation-protected lease income, holding Parkway Life shares may be appropriate for investors seeking stable income and long-term growth. Market sentiment and fundamentals suggest continued strength in the medium to long term.
Are dividends from Parkway Life stock taxed in Singapore?
Dividends from Parkway Life REIT are generally not subject to further taxation for individual investors in Singapore. Most distributions are tax-exempt, as the REIT passes on taxable income after paying the requisite tax at the trust level. There is no withholding tax on REIT distributions for Singapore-resident individuals, making it a tax-efficient investment for local investors.
What is the latest dividend for Parkway Life stock?
Parkway Life REIT currently pays a dividend. For Q1 2025, the distribution per unit (DPU) was 3.84 Singapore cents, paid quarterly. For the full year 2024, the DPU was 14.92 cents, reflecting a steady, gradual increase from previous years. The current dividend yield is around 3.55%. Parkway Life maintains a consistent distribution policy, supported by long-term master leases and CPI-linked rent revisions.
What is the forecast for Parkway Life stock in 2025, 2026, and 2027?
Based on the latest share price of SGD 4.23, the projected prices are SGD 5.50 for end-2025, SGD 6.34 for end-2026, and SGD 8.46 for end-2027. The healthcare real estate sector remains robust, and Parkway Life's recent expansion into France provides additional growth drivers. Analysts continue to view the REIT positively due to its defensive sector exposure and consistent performance.
Should I sell my Parkway Life shares?
Parkway Life REIT has demonstrated resilience, benefiting from defensive assets in the healthcare sector and a strong track record of steady distributions. Given its ongoing growth through recent acquisitions, stable balance sheet, and inflation-protected lease income, holding Parkway Life shares may be appropriate for investors seeking stable income and long-term growth. Market sentiment and fundamentals suggest continued strength in the medium to long term.
Are dividends from Parkway Life stock taxed in Singapore?
Dividends from Parkway Life REIT are generally not subject to further taxation for individual investors in Singapore. Most distributions are tax-exempt, as the REIT passes on taxable income after paying the requisite tax at the trust level. There is no withholding tax on REIT distributions for Singapore-resident individuals, making it a tax-efficient investment for local investors.
